Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + KRd in Newly Diagnosed Multiple Myeloma
NCT04113018Phase 2Active, not recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jan 2020
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Wake Forest University Health Sciences. Started Jan 2020; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04113018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04113018.